An interventional study of Sinus Stenting in Treatment of Symptomatic Lateral Sinus Stenosis and Treatment of Pulsatile Tinnitus Due tu Sinus Stenosis, sponsored by Acandis GmbH. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Acandis GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Tinnitus with a site in France — 11 open to participants now, 11 under way, none of them phase 3. Tinnitus · France.
Among the 29 studies in Tinnitus with a site in France, this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 24th registered.
446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.
Browse Tinnitus studies →11 of the 29 studies in Tinnitus with a site in France are open now. Recruiting first, the newest first:
V-Flow 21 · Sites in France
Ages 18+
Sonorous NV, Inc · Sites in France, Canada
Ages 18–80
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18–84
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 60 across 370 interventional studies indexed under Tinnitus.
Median enrollment 71 across the 24 interventional studies, 40 across the 5 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 29 have an industry lead sponsor. The 10 most frequent:
Acandis GmbH is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Acandis GmbH has 1 study filed under Tinnitus — fewer than ten, so there is no comparison to draw.
5 of the studies in Tinnitus with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726928Acandis GmbHSiREX-Stent for the Treatment of SymptOmatic Lateral VEnous Sinus Stenosis | 2027-01 |
| NCT07070089Sonorous NV, IncBosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous Tinnitus | 2027-07 |
| NCT05946577Assistance Publique - Hôpitaux de ParisAssociation Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study | 2027-07-09 |
| NCT07515781V-Flow 21VivaStent Feasibility Study | 2027-08 |
| NCT04717388Assistance Publique - Hôpitaux de ParisPathophysiology, Psycho-emotional and Cognitive Functioning Associated With Tinnitus | 2027-10-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 29 studies in Tinnitus with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy, safety and the clinical benefit of the SiREX stent for the treatment of disabling pulsatile tinnitus due to stenosis of lateral sinus.
The study will enrol patients suffering from pulsatile tinnitus related to a lateral sinus stenosis lasting more than three months, and who want to be treated with lateral sinus stenting
As there is currently no specifically developed and approved stent on the market for the treatment of symptomatic sinus stenosis, stenting has so far been performed with stents intended for carotid stenosis or peripheral treatment, which leads to considerable limitations. Because of stiff delivery systems (6F or bigger) progression inside the venous sinus is sometimes difficult. Furthermore, the length of such devices is often insufficient to cover the entire pathological segment and more than one device needs to be implanted in an overlaying manor (telescoping), which is accompanied with higher complication risks.
The objective of the study is to prove the efficacy and clinical safety of the new dedicated SiREX Stent with optimized technical features (smaller delivery system, longer lengths, reduced radial force), specially developed for the treatment of venous sinus stenosis. Pulsatile tinnitus is expected to disappear immediately after treatment with a stable effect during time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient ≥ 18 years old
Exclusion Criteria:
Any for treatment according to Instructions for Use:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Novel medical device
Device: Sinus Stenting
Stenting of symptomatic sinus stenosis
Disappearance of pulsatile tinnitus at 90 (± 20) days
Disappearance of pulsatile tinnitus at 90 (± 20) days after resolving of the lateral sinus stenosis with SiREX Stent
Time frame: 90 days
Start is estimated for Sep 2025; primary completion for Jan 2027, 16 months later.
Of 153 interventional studies with no phase under Tinnitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 16 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acandis GmbH